ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated Incurable Ewing Sarcoma

  • STATUS
    Recruiting
  • End date
    Apr 18, 2021
  • participants needed
    41
  • sponsor
    Sarcoma Alliance for Research through Collaboration
Updated on 13 January 2021
Investigator
SARC Office
Primary Contact
National Cancer Institute (9.7 mi away) Contact
+4 other location
cyclophosphamide
immunosuppressive
measurable disease
cell transplantation
doxorubicin
irinotecan
cancer chemotherapy
temozolomide
ifosfamide

Summary

The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.

Details
Treatment Temozolomide, Irinotecan, Niraparib
Clinical Study IdentifierNCT02044120
SponsorSarcoma Alliance for Research through Collaboration
Last Modified on13 January 2021

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet